文献速递淋巴瘤造血干细胞移植与细胞治疗

标准治疗阿基仑赛治疗大B细胞淋巴瘤的五年随访:美国淋巴瘤CAR-T联盟结果

Five-Year Follow-Up of Standard-of-Care Axicabtagene Ciloleucel for Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium.
PubMed 文献 · J Clin Oncol · 2024-08-02

该研究对298例接受白细胞分离、拟接受标准治疗阿基仑赛(axi-cel)的复发或难治性大B细胞淋巴瘤患者(其中275例输注)进行中位58个月延长随访,5年无进展生存率29%、总生存率40%,5年非复发死亡率16.2%,晚期非复发死亡主要归因于感染和第二原发恶性肿瘤。

要点

  • 输注患者5年无进展生存率29%,5年总生存率40%,5年淋巴瘤特异性生存率53%。
  • 5年非复发死亡率16.2%,其中超过一半的非复发死亡事件发生在2年之后。
  • ≥60岁患者复发风险较低(P=0.02),但非复发死亡风险较高(OR 4.5,95%CI 2.1-10.8;P<0.001)。

核心结论

  • 在标准治疗背景下,阿基仑赛的结局与临床试验报告一致,5年时点观察到持续、持久的缓解。
  • 晚期感染和第二原发恶性肿瘤是降低CAR-T细胞治疗后长期生存的关键生存问题,尤其在老年患者中。

研究设计与样本

  • 对既往报告的298例接受白细胞分离、拟接受标准治疗阿基仑赛(输注275例)且既往接受≥2线治疗的复发或难治性大B细胞淋巴瘤患者队列进行延长随访。
  • 本次报告中位随访时间为58个月,重点分析晚期生存事件。

主要发现

  • 输注患者5年无进展生存率为29%,5年总生存率为40%。
  • 5年淋巴瘤特异性生存率为53%,晚期复发少见。
  • 5年非复发死亡率为16.2%,超过一半的非复发死亡事件发生在2年之后。
  • ≥60岁患者较<60岁患者复发风险较低(P=0.02),但非复发死亡风险较高(非复发死亡比值比4.5,95%CI 2.1-10.8;P<0.001)。
  • 晚期非复发死亡主要归因于感染和第二原发恶性肿瘤;第二原发恶性肿瘤共发生于24例患者(9%),包括治疗相关髓系肿瘤15例、实体瘤7例、无关淋巴系统恶性肿瘤2例。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Axicabtagene ciloleucel (axi-cel) is an autologous CD19 chimeric antigen receptor (CAR) T-cell therapy that is approved for the treatment of relapsed or refractory large B-cell lymphoma. Little is known about the long-term survivorship after CAR T-cell therapy. METHODS: We previously reported the results of 298 patients who were leukapheresed with the intent to receive standard-of-care axi-cel (n = 275 infused) after two or more previous lines of therapy at a median follow-up of 12.9 months. Here, we report extended follow-up of this cohort to a median of 58 months, with a focus on late survivorship events. RESULTS: Among axi-cel-infused patients, progression-free survival at 5 years was 29% and overall survival (OS) at 5 years was 40%. The 5-year lymphoma-specific survival was 53% with infrequent late relapses. However, the 5-year nonrelapse mortality (NRM) was 16.2%, with over half of NRM events occurring beyond 2 years. Patients who were 60 years and older had a lower risk of relapse (P = .02), but a higher risk of NRM compared with patients younger than 60 years (NRM odds ratio, 4.5 [95% CI, 2.1 to 10.8]; P < .001). Late NRM was mainly due to infections and subsequent malignant neoplasms (SMNs). In total, SMNs occurred in 24 patients (9%), including therapy-related myeloid neoplasms (n = 15), solid tumors (n = 7), and unrelated lymphoid malignancies (n = 2). CONCLUSION: In the standard-of-care setting, axi-cel exhibits outcomes consistent with those reported in clinical trials, with sustained, durable responses observed at the 5-year time point. However, late infections and the development of SMN are key survivorship issues that reduce long-term survival after CAR T-cell therapy, particularly in the elderly.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Jain MD, Spiegel JY, Nastoupil LJ, et al. Five-Year Follow-Up of Standard-of-Care Axicabtagene Ciloleucel for Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium. J Clin Oncol. 2024. PMID: 39094076. doi:10.1200/JCO.23.02786

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。